BRPI0511250A - composto de tiazol e uso deste - Google Patents

composto de tiazol e uso deste

Info

Publication number
BRPI0511250A
BRPI0511250A BRPI0511250-8A BRPI0511250A BRPI0511250A BR PI0511250 A BRPI0511250 A BR PI0511250A BR PI0511250 A BRPI0511250 A BR PI0511250A BR PI0511250 A BRPI0511250 A BR PI0511250A
Authority
BR
Brazil
Prior art keywords
group
alkylene
compound
following groups
relates
Prior art date
Application number
BRPI0511250-8A
Other languages
English (en)
Inventor
Isao Takemura
Kenji Watanabe E Katsuji Baba
Kunio Oshima
Nobuhaki Ito
Junpei Haruta
Hidetaka Hiyama
Masatoshi Chihiro
Hideki Kawasome
Yoko Sakamoto
Hironobu Ishiyama
Takumi Sumida
Kazuhiko Fujita
Hideki Kitagaki
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of BRPI0511250A publication Critical patent/BRPI0511250A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

COMPOSTO DE TIAZOL E USO DESTE A presente invenção refere-se a um novo composto de tiazol com atividade inibidora especifica contra fosfodiesterase 4. A presente invenção refere-se um composto representado pela fórmula (1), um isómero óptico deste, ou um sal deste: em que R1 é um grupo de di-C~ 1~-~ 6~ alcoxifenila; R2 é qualquer um dos seguintes grupos (a) a (t): (a) um grupo de fenila; (b) um grupo de naftila; (c) um grupo de piridila: (d) um grupo de furila; (e) um grupo de tienila; (f) um grupo de isoxazolila; (g) um grupo de tiazolila; (h) um grupo de pirrolila; (i) um grupo de imidazolila; (j) um grupo de tetrazolila; (k) um grupo de pirazinila; (L) um grupo de tienotienila; (m) um grupo de benzotienila; (n) um grupo de indolila; (o) um grupo de benzimidazolila; (p) um grupo de indazolila; (q) um grupo de quinolila; (r) um grupo de 1 ,2,3,4-tetraidroquinolila; (s) um grupo de quinoxalinila; e (t) um grupo de 1 ,3-benzodioxolila; e A é qualquer um dos seguintes grupos (i) a (vi): (i) -CO-B- em que B é um grupo de e C~ 1~-~ 6~ alquileno; (ii) -CO-Ba- em que Ba é um grupo de C~ 2~-~ 6~alquenileno; (iii) -CH(OH)-B-; (iv) -COCH(COOR3)-Bb- em que R3 é um grupo de C~ 1~-~ 6~ alquila e Bb é um grupo de C~ 1~-~ 6~ alquileno; e (v) -Bc- em que Bc é um grupo de C~ 2~-~ 6~ alquileno.
BRPI0511250-8A 2004-05-17 2005-05-16 composto de tiazol e uso deste BRPI0511250A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004146834 2004-05-17
PCT/JP2005/008873 WO2005111007A1 (ja) 2004-05-17 2005-05-16 チアゾール化合物及びその用途

Publications (1)

Publication Number Publication Date
BRPI0511250A true BRPI0511250A (pt) 2007-11-27

Family

ID=35394118

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0511250-8A BRPI0511250A (pt) 2004-05-17 2005-05-16 composto de tiazol e uso deste

Country Status (12)

Country Link
US (2) US7655680B2 (pt)
EP (1) EP1748044A4 (pt)
JP (1) JP4925821B2 (pt)
KR (1) KR101242310B1 (pt)
CN (2) CN102816130B (pt)
AU (1) AU2005243384A1 (pt)
BR (1) BRPI0511250A (pt)
CA (1) CA2566625C (pt)
MX (1) MXPA06013305A (pt)
RU (1) RU2379298C2 (pt)
TW (1) TW200600507A (pt)
WO (1) WO2005111007A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006316079B2 (en) 2005-11-15 2012-03-29 Otsuka Pharmaceutical Co., Ltd. Oxazole compound and pharmaceutical composition
JP6012468B2 (ja) * 2009-10-02 2016-10-25 アヴェクシン エーエス 抗炎症性２−オキソチアゾールおよび２−オキソオキサゾール
US8809372B2 (en) 2011-09-30 2014-08-19 Asana Biosciences, Llc Pyridine derivatives
CN105102438B (zh) 2013-01-29 2019-04-30 埃维克辛公司 抗炎症和抗肿瘤的2-氧代噻唑类和2-氧代噻吩类化合物
GB201413695D0 (en) 2014-08-01 2014-09-17 Avexxin As Compound
EP3186237A1 (en) 2014-08-28 2017-07-05 Medizinische Universität Wien Heteroaromatic chalcone derivatives and their medical use
LT6401B (lt) * 2015-07-28 2017-06-12 Vilniaus Universitetas Karboanhidrazės selektyvūs inhibitoriai
WO2017100645A2 (en) * 2015-12-10 2017-06-15 Rutgers, The State University Of New Jersey Inhibitors of bacterial rna polymerase: arylpropanoyl, arylpropenoyl, and arylcyclopropanecarboxyl phloroglucinols
GB201604318D0 (en) 2016-03-14 2016-04-27 Avexxin As Combination therapy
US11572337B2 (en) 2018-03-06 2023-02-07 Rutgers, The State University Of New Jersey Antibacterial agents: arylalkylcarboxamido phloroglucinols
WO2021029659A1 (ko) * 2019-08-12 2021-02-18 연세대학교 산학협력단 에틸바닐린, 수베르산, 티아졸 또는 이의 염을 유효성분으로 포함하는 알러지성 질환 또는 아토피 피부염 예방 또는 치료용 조성물
KR102076936B1 (ko) * 2019-08-12 2020-02-13 연세대학교 산학협력단 티아졸 또는 이의 염을 유효성분으로 포함하는 알러지성 질환 또는 아토피 피부염 예방 또는 치료용 조성물

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2413935A1 (de) * 1974-03-20 1975-10-16 Schering Ag 4-(polyalkoxy-phenyl)-2-pyrrolidone
US4193926A (en) 1974-03-20 1980-03-18 Schering Aktiengesellschaft 4-(Polyalkoxy phenyl)-2-pyrrolidones
NL7800644A (nl) * 1978-01-19 1979-07-23 Stamicarbon Werkwijze voor de bereiding van 2-pyrrolidon.
US4826990A (en) 1987-09-30 1989-05-02 American Home Products Corporation 2-aryl substituted heterocyclic compounds as antiallergic and antiinflammatory agents
AU634608B2 (en) * 1989-12-09 1993-02-25 Kyoyu Agri Co., Ltd. 2-substituted phenyl-2-oxazoline or thiazoline derivatives, process for producing the same and insectides and acaricides containing the same
CA2074933C (en) * 1990-11-30 2002-12-03 Masatoshi Chihiro Thiazole derivatives as active superoxide radical inhibitors
BR9307570A (pt) 1992-12-02 1999-05-25 Pfizer Diéteres de catecol como inibidores seletivos de pdeiv
US5814651A (en) * 1992-12-02 1998-09-29 Pfizer Inc. Catechol diethers as selective PDEIV inhibitors
AU4015497A (en) * 1996-08-26 1998-03-19 Byk Gulden Lomberg Chemische Fabrik Gmbh Thiazole derivatives useful as selective inhibitors of pde-iv
OA12542A (en) * 2001-01-31 2006-06-05 Pfizer Prod Inc Thiazolyl-, oxazolyl-, pyrrolyl-, and imidazolyl-acid amide derivatives useful as inhibitors of PDE4isozymes.
ATE417038T1 (de) 2001-06-15 2008-12-15 Astellas Pharma Inc Phenylpyridincarbonyl piperazinderivate
US6472386B1 (en) 2001-06-29 2002-10-29 Kowa Co., Ltd. Cyclic diamine compound with 5-membered ring groups
DE60316810T2 (de) 2002-08-02 2008-07-17 Ab Science 2-(3-aminoaryl)amino-4-aryl-thiazole und ihre verwendung als c-kit inhibitoren

Also Published As

Publication number Publication date
KR20070011609A (ko) 2007-01-24
US20100094002A1 (en) 2010-04-15
CN102816130A (zh) 2012-12-12
MXPA06013305A (es) 2007-02-02
US7655680B2 (en) 2010-02-02
WO2005111007A1 (ja) 2005-11-24
RU2006144835A (ru) 2008-06-27
EP1748044A1 (en) 2007-01-31
CA2566625C (en) 2014-01-07
KR101242310B1 (ko) 2013-03-12
JPWO2005111007A1 (ja) 2008-03-21
AU2005243384A1 (en) 2005-11-24
CN102816130B (zh) 2015-05-06
RU2379298C2 (ru) 2010-01-20
CN1953968A (zh) 2007-04-25
TW200600507A (en) 2006-01-01
CN1953968B (zh) 2012-10-10
CA2566625A1 (en) 2005-11-24
EP1748044A4 (en) 2007-12-12
JP4925821B2 (ja) 2012-05-09
US8450352B2 (en) 2013-05-28
US20080039511A1 (en) 2008-02-14

Similar Documents

Publication Publication Date Title
BR112012003955A2 (pt) compostos heterocíclicos tricíclicos como inibidores da fosfoinositídeos 3-quinase
WO2007103550A3 (en) Substituted aminothiazole derivatives with anti-hcv activity
BR122017028096B8 (pt) composto, composição farmacêutica, e, uso do composto
BR112012020986A2 (pt) composto de amina cíclica e acaricida
HRP20020751B1 (hr) Pirolom supstituirani 2-indolinoni kao inhibitori protein kinaze
BRPI0821653B8 (pt) composto de piridina substituída com anel heterocíclico e grupo fosfonoximetila ou um sal do mesmo, composição farmacêutica compreendendo-os e uso dos mesmos para tratar uma doença fungíca
WO2003090539A8 (de) 3-heteroarylsubstituierte 5 methyloxymethyl-isoxazoline als herbizide
WO2003039451A3 (en) Thiazole pyridazinones as adenosine antagonists
ATE331716T1 (de) Nicht-nukleosidische inhibitoren der reverse transkriptase
TW200600507A (en) Thiazole compound and use thereof
TR28289A (tr) N-fenilkarbamat bilesigi, bu bilesigin hazirlanmasi ve zararli organizmalarin kontrolü icin biyosidal bilesim.
AR094123A1 (es) Compuesto triciclicos
NO20073787L (no) Nye pyrimidin-nukleosidforbindelser eller dets salt
EA200901084A1 (ru) Способ выработки у растений устойчивости к вирусу
TNSN07439A1 (en) Derivatives of,4,5 - diarylpyrrole, preparation method thereof and use of same in therapeutics
DE602004028515D1 (de) Wässrige lösung zur verwendung als medium für die spezifischen bindungsreaktion eines bindespaares
CA2615466A1 (en) Benzofused five-membered heterocycles as inhibitors of catechol-o-methyltransferase (comt) enzyme
DE602006007441D1 (de) Chinazolinderivate als antivirale mittel
ATE337327T1 (de) Substituierte ferrocenyldiphosphinligande für homogene hydrogenieringskatalysatoren
WO2008156102A1 (ja) ピラゾロン誘導体及びそれらを有効成分とするｐｄｅ阻害剤
MA27077A1 (fr) Derives de 2-amino-4-heteroarylethyl thiazoline et leur utilisation comme inhibiteurs de no-synthase inductible
BRPI0415073A (pt) azaciclos n-substituìdos
MX2010008740A (es) Derivado de 3,8-diaminotetrahidroquinolina.
WO2009022720A1 (ja) ５員複素環化合物
EP1908752A4 (en) NEW 2-CHINOLO DERIVATIVES

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.